Valuation: ProPhase Labs, Inc.

Market Cap 1.09M 956K 878K 819K 1.55M 104M 1.58M 10.54M 4.1M 51.17M 4.1M 4.02M 176M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.62M 8.41M 7.73M 7.2M 13.67M 916M 13.87M 92.8M 36.07M 450M 36.11M 35.34M 1.55B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-2.50%
1 week-22.00%
Current month-15.22%
1 month-37.60%
3 months-10.14%
6 months-78.49%
Current year-82.57%
1 week 0.07
Extreme 0.0712
0.11
1 month 0.07
Extreme 0.0712
0.12
Current year 0.07
Extreme 0.068
0.47
1 year 0.07
Extreme 0.068
6.66
3 years 0.07
Extreme 0.068
75.9
5 years 0.07
Extreme 0.068
152.5
10 years 0.07
Extreme 0.068
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25Free

Chief Executive Officer

500,000 1.2036%
17/02/25Free

Chief Operating Officer

500,000 1.6737%
14/02/25Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-2.50%-22.00%-98.14%-99.89% 1.09M
+1.10%+6.65%+72.68%+472.96% 40B
+1.09%+5.71%+9.58%+37.36% 23.53B
+1.58%+4.06%-20.86%-40.58% 7.28B
+4.77%+13.19%+22.33%+117.22% 5.41B
-0.28%-2.58%+19.40%+46.08% 2.89B
-5.86%-3.31%-26.31%+1,042.30% 2B
+1.27%+6.99%+100.79%-3.93% 1.97B
-0.44%+7.04%+38.49%-21.35% 1.82B
+2.08%+0.70%+22.24%-3.56% 1.65B
Average +0.28%+2.96%+14.02%+154.66% 8.66B
Weighted average by Cap. +1.15%+6.85%+39.40%+257.69%

Financials

2024 2025
Net sales 6.77M 5.92M 5.44M 5.07M 9.62M 645M 9.76M 65.3M 25.38M 317M 25.41M 24.87M 1.09B 4.34M 3.8M 3.49M 3.25M 6.17M 414M 6.27M 41.91M 16.29M 203M 16.31M 15.96M 701M
Net income -53.36M -46.65M -42.87M -39.96M -75.8M -5.08B -76.95M -515M -200M -2.5B -200M -196M -8.61B -14.74M -12.89M -11.84M -11.04M -20.94M -1.4B -21.26M -142M -55.28M -690M -55.34M -54.15M -2.38B
Net Debt 23.9M 20.89M 19.2M 17.89M 33.94M 2.28B 34.45M 230M 89.59M 1.12B 89.69M 87.77M 3.85B 8.53M 7.46M 6.85M 6.39M 12.11M 812M 12.3M 82.25M 31.97M 399M 32.01M 31.32M 1.38B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
02/07/26 $0.0780 -2.50% 271,949
01/07/26 $0.0800 -13.04% 1,137,274
30/06/26 $0.0920 -2.19% 12,952
29/06/26 $0.0941 -5.94% 46,245
26/06/26 $0.1000 +9.77% 23,213

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock